New tablet could scratch the itch for dialysis patients
NCT ID NCT07098351
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tests whether nalfurafine hydrochloride tablets can safely reduce moderate-to-severe itching in people undergoing peritoneal dialysis. About 93 participants will take the drug daily for up to 4 weeks, and their itch levels will be measured using a simple 0-to-10 scale. The goal is to see if this medication offers meaningful relief for a common and distressing symptom.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nalfurafine hydrochloride (orally disintegrating tablet)
What this could lead to
If it works, this could provide a new treatment option for severe itching in people on peritoneal dialysis, improving their comfort and daily life.
What could go wrong
This is a small, early-phase trial with no placebo group, so results may not be definitive. The drug may cause side effects or not work for everyone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVERSE EVENT are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Guangdong Provincial People's Hospital
RECRUITINGGuangzhou, Guangdong, 510080, China
Contact